The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery
Status:
Recruiting
Trial end date:
2021-12-20
Target enrollment:
Participant gender:
Summary
Total hip arthroplasty (THA) is associated with blood loss ranging from 300 to 2000 mL.
Tranexamic acid (TXA) is frequently administered prophylactically during this procedure to
reduce blood loss by inhibiting fibrinolysis or by stopping naturally occurring clot
resolution. TXA is employed currently based on a surgeon's preference. The objective of this
study is to quantitate the degree of fibrinolysis using rotational thromboelastometry (ROTEM)
and investigate the role of TXA prophylaxis on blood loss in patients undergoing THA in a
double-blind fashion. Our hypothesis is that fibrinolysis is minimal at most and TXA
prophylaxis is not necessary during THA. All patients, whether they receive TXA or normal
saline, will not be at risk, as at this time no data exists to determine which approach is
safer or more effective. This is the first study to compare TXA vs. placebo in a
double-blinded, randomized controlled trial.